The Role of MicroRNA in the Diagnosis Prognosis and Response to Treatment in Pancreatic Cancer

  • STATUS
    Recruiting
  • End date
    Apr 5, 2027
  • participants needed
    100
  • sponsor
    Western Connecticut Health Network
Updated on 19 February 2024
cancer
measurable disease
metastasis
adenocarcinoma
endocrine therapy
early diagnosis
carcinoma
pancreatic adenocarcinoma
metastatic pancreatic cancer
pancreaticoduodenectomy
systemic therapy
blood draw
adjuvant therapy
microrna
mirna
recurrent disease
malignancy
other malignancy
inoperable disease
pancreatic cancer
pancreatoduodenectomy

Summary

Aberrant miRNA production has been linked to a wide range of human cancers and shown to play important roles in their genesis and growth. These miRNA can be detected in the blood and tumors of patients with cancer. We hypothesize that the detection of certain miRNAs present in the blood/serum of patients with pancreatic cancer may be important to the early diagnosis of the disease. Furthermore, we hypothesize that miRNA detection in PC patients will yield prognostic information and help predict the response to treatment.

Details
Condition Pancreatic Cancer, Pancreatic Cancer, Pancreatic disorder, Neoplasm of unspecified nature of digestive system, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV
Age 18-100 years
Treatment Blood Draw
Clinical Study IdentifierNCT04406831
SponsorWestern Connecticut Health Network
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Have biopsy proven adenocarcinoma of the pancreas
Have initially inoperable disease, classified as either locally advanced or metastatic disease
Recurrent disease after a Whipple procedure is allowed
Patients who are able to undergo resection after neoadjuvant therapy will continue to be followed after resection
Have radiographically measurable disease
Have an ECOG performance status of < 2
Be willing to contribute the required information and specimens
Provide written signed consent to participate
Have received no prior anti-cancer treatments for metastatic pancreatic cancer
Be eligible to receive multi-agent chemotherapy for the first line treatment of pancreatic cancer
Have a predicted life expectancy of at least 3 months
Not be concurrently receiving systemic therapy for another cancer except androgen deprivation therapy for stable/controlled prostate cancer
No other active cancer except for: adequately treated local basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for >1 year prior to start of trial. Other adequately treated Stage 1 or 2 cancer currently in complete remission, or any other cancer that has been in complete remission for > 5 years is allowable
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.